Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY24 results · Apr–Jun 2023
Suven Life Sciences reported revenue from operations of ₹3.80 crore (up 7.3% from Q1 FY23) and net loss of ₹24.09 crore for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.80 | 3.54 | +7.3% | 2.61 | +45.4% |
| Other income | 5.64 | 0.44 | 13x | 5.60 | +0.7% |
| Total income | 9.44 | 3.98 | +137.4% | 8.21 | +14.9% |
| Profit before tax | (24.09) | (16.33) | Loss widened | (27.64) | Loss narrowed |
| Net profit for the period | (24.09) | (16.33) | Loss widened | (27.64) | Loss narrowed |
| EPS, basic (₹) | (1.10) | (1.12) | not comparable | (1.17) | Loss narrowed |
| Net margin (%) | -634.4 | -461.3 | -1058.7 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.80 | 3.54 | +7.3% | 2.61 | +45.4% |
| Other income | 5.64 | 0.44 | 13x | 5.60 | +0.7% |
| Total income | 9.44 | 3.98 | +137.4% | 8.21 | +14.9% |
| Profit before tax | (2.87) | (2.31) | Loss widened | (2.25) | Loss widened |
| Net profit for the period | (2.87) | (2.31) | Loss widened | (2.25) | Loss widened |
| EPS, basic (₹) | (0.13) | (0.16) | not comparable | (0.05) | Loss widened |
| Net margin (%) | -75.6 | -65.3 | -86.1 |
Consolidated
- Filed with BSE
- 08 Aug 2023, 17:01 IST
- Board meeting
- 08 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2023, 17:01 IST
- Board meeting
- 08 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE